# **Munich Cancer Registry**



- ▶ Incidence and Mortality
- ▶ Selection Matrix
- ▶ Homepage
- ▶ Deutsch

## ICD-10 C50: Breast cancer (women)

## Survival


Year of diagnosis	1988-1997	1998-2014
Patients	11,838	53,128
Diseases	12,318	55,500
Cases evaluated	10,582	43,060
Creation date	04/11/2016	
Export date	12/23/2015	



Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany

http://www.tumorregister-muenchen.de/en

http://www.tumorregister-muenchen.de/en/facts/surv/sC50f\_E-ICD-10-C50-Breast-cancer-women-survival.pdf



**Figure 1a.** Relative survival of patients with breast cancer (women) by period of diagnosis. Included in the evaluation are 53,166 cases diagnosed between 1988 and 2014.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

	F	Period	of diag	gnosis	•	
	1988-	1997	1998-	2006	200	)7+
	n=10	,558	n=18	,977	n=23	,631
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0
1	96.4	98.0	95.8	97.5	96.1	97.6
2	91.4	94.4	91.4	94.6	92.1	95.1
3	86.1	90.4	87.2	91.7	88.1	92.4
4	80.9	86.4	83.5	89.2	84.8	90.3
5	76.5	83.1	79.9	86.8	82.0	88.6
6	72.5	80.0	76.9	84.8	79.2	87.0
7	68.8	77.3	73.7	82.6	76.5	85.4
8	66.0	75.3	71.1	81.0	73.9	83.6
9	63.2	73.4	68.6	79.5		
10	60.8	71.8	65.9	77.6		
11	58.4	70.2	63.7	76.3		
12	55.7	68.1	61.5	75.1		
13	53.3	66.5	59.2	73.6		
14	51.1	64.8	57.5	72.9		
15	48.8	63.1	55.5	71.7		
16	46.7	61.6	53.7	70.8		
17	44.9	60.4				
18	43.0	59.1				
19	41.0	57.5				
20	39.5	56.5				

**Table 1b.** Observed (obs.) and relative (rel.) survival of patients with breast cancer (women) by period of diagnosis for period 1988-2014 (N=53,166).




Figure 1c. Relative survival of patients with breast cancer (women) by year of diagnosis. Included in the evaluation are 42,608 cases diagnosed between 1998 and 2014.


The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 1998 to 2011, and are represented by gray diamonds in order to facilitate comparisons between MCR and SEER.

						Year o	of diag	nosis						
	19	98	19	99	20	00	20	01	200	02	20	03	20	04
	n=1,	489	n=1,	,581	n=1,	544	n=1,	569	n=2,	588	n=2,	434	n=2,	547
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	93.9	95.7	95.7	97.4	96.2	97.9	96.3	97.8	96.4	98.1	95.7	97.3	96.0	97.6
2	90.5	93.7	91.4	94.6	92.4	95.7	91.7	94.7	91.5	94.7	90.8	94.0	91.8	94.9
3	85.6	90.1	87.4	92.0	87.5	92.3	88.1	92.2	87.0	91.6	86.2	90.8	87.2	91.6
4	82.2	88.0	83.0	88.8	82.8	88.7	83.7	89.0	83.3	89.1	81.8	87.6	84.2	89.8
5	78.0	84.9	79.4	86.3	77.8	84.9	79.7	86.0	79.9	87.0	78.5	85.4	81.0	87.8
6	75.0	83.0	76.6	84.7	75.4	83.6	76.9	84.0	76.8	84.9	75.4	83.4	77.9	85.8
7	71.1	79.9	73.7	82.7	72.5	81.8	74.4	82.6	73.0	82.0	71.9	80.9	74.5	83.2
8	67.5	77.1	71.0	81.0	69.2	79.3	72.0	81.1	70.8	80.9	69.6	79.6	72.5	82.3
9	65.3	75.7	68.7	79.7	67.0	77.9	69.9	80.0	67.9	78.9	67.4	78.4	69.6	80.2
10	62.4	73.7	66.0	77.8	64.5	76.4	67.7	78.6	65.0	77.0	64.2	76.1	66.5	78.0
11	59.5	71.4	63.4	76.1	62.5	75.2	65.3	77.2	62.9	75.8	62.2	75.1		
12	57.1	69.8	61.4	75.0	60.3	73.8	63.5	76.3	60.8	74.8				
13	55.1	68.6	58.5	72.8	58.0	72.3	61.5	75.3						
14	53.6	67.9	57.1	72.1	55.8	70.9								
15	51.4	66.4	54.9	71.0										

						Year o	of diag	nosis						
cont'd	20	05	20	06	20	07	20	80	20	09	20	10	20	11
	n=2,	599	rel. % obs. % rel. %		n=2,	882	n=3,	173	n=3,	168	n=3,	136	n=3,	000
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	95.7	97.4	95.7	97.3	95.9	97.5	95.7	97.3	96.8	98.3	95.9	97.4	95.7	97.3
2	91.5	94.7	91.4	94.3	91.5	94.6	91.9	94.8	92.9	95.7	92.4	95.4	91.7	94.7
3	87.4	91.8	88.2	92.3	87.4	91.9	87.8	92.0	88.6	92.7	88.4	92.6	87.8	92.1
4	83.8	89.5	85.6	91.0	83.9	89.7	84.3	89.7	85.4	90.7	85.0	90.5		
5	80.7	87.6	82.4	88.9	80.1	86.9	81.5	88.1	82.9	89.4	83.2	89.6		
6	77.3	85.3	79.1	86.7	77.0	84.9	79.3	86.9						
7	74.7	83.7	76.1	84.8	74.0	83.0								
8	71.9	82.0	73.7	83.4	71.5	81.2								
9	69.1	80.1												

Year of diagnosis cont'd 2012 2013 2014														
cont'd	20	12	20	13	20	14								
	n=3,	140	n=2,	893	n=2,	239								
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %								
0	100.0	100.0	100.0	100.0	100.0	100.0								
1	95.6	97.1	96.3	97.9	97.3	98.5								
2	91.2	94.2	93.5	96.3										
3	88.3	92.3												


**Table 1d.** Observed (obs.) and relative (rel.) survival of patients with breast cancer (women) by year of diagnosis for period 1998-2014 (N=42,608).




**Figure 2a.** Observed, expected and relative survival of the total cohort with breast cancer (women). Included in the evaluation are 53,166 cases diagnosed between 1988 and 2014.

	Group	
	Total of	cohort
	n=53	,166
Years	obs. %	rel. %
0	100.0	100.0
1	96.0	97.6
2	91.7	94.8
3	87.3	91.7
4	83.4	88.9
5	79.8	86.5
6	76.5	84.3
7	73.2	81.9
8	70.5	80.2
9	67.8	78.5
10	65.1	76.7
11	62.8	75.3
12	60.2	73.5
13	57.8	71.9
14	55.7	70.4
15	53.3	68.8
16	51.2	67.4
17	49.2	66.1
18	47.2	64.7
19	44.9	62.9
20	43.3	61.9

**Table 2b.** Observed (obs.) and relative (rel.) survival of the total cohort with breast cancer (women) for period 1988-2014 (N=53,166).



**Figure 3a.** Observed survival of patients with breast cancer (women) by age category. Included in the evaluation are 53,166 cases diagnosed between 1988 and 2014.




**Figure 3b.** Relative survival of patients with breast cancer (women) by age category. Included in the evaluation are 53,166 cases diagnosed between 1988 and 2014.

					Age	categ	ory					
	0-39	yrs	40-49	9 yrs	50-59	9 yrs	60-6	9 yrs	70-7	9 yrs	80+	yrs
	n=2,	919	n=9,	260	n=12	,725	n=13	,789	n=9,	412	n=5,	,061
Years	obs. %	rel. %										
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	98.4	98.5	98.4	98.6	98.1	98.4	97.4	98.3	94.2	96.5	84.7	93.5
2	94.8	94.9	95.8	96.1	95.0	95.7	94.5	96.2	88.6	93.3	72.0	88.2
3	90.9	91.0	92.6	93.1	92.0	93.1	91.0	93.5	83.3	90.4	61.1	83.6
4	87.3	87.5	90.0	90.6	89.3	90.8	88.0	91.5	77.9	87.4	51.7	79.7
5	84.1	84.4	87.5	88.3	86.7	88.6	85.2	89.6	73.2	85.3	43.4	75.8
6	81.3	81.6	85.5	86.5	84.5	86.8	82.4	87.8	68.4	83.2	35.8	71.9
7	78.8	79.1	83.3	84.5	82.1	84.8	79.7	86.1	63.2	80.6	29.4	68.4
8	76.5	76.9	81.5	83.0	80.2	83.5	77.5	85.1	58.5	78.8	24.4	66.4
9	74.5	75.1	79.9	81.5	78.3	82.0	75.1	83.9	54.3	77.5	19.4	63.0
10	72.3	72.9	78.3	80.3	76.6	80.8	72.5	82.6	49.7	76.1	14.7	57.8
11	71.2	72.0	76.7	78.9	74.9	79.7	70.0	81.4	45.4	74.9	12.1	56.4
12	69.4	70.1	75.2	77.7	73.6	79.0	67.2	80.1	40.0	71.6		
13	67.5	68.3	73.6	76.4	71.9	77.9	64.3	78.8	35.6	70.1		
14	65.9	66.9	72.0	75.0	70.2	76.9	61.5	77.6	32.1	69.1		
15	64.5	65.6	70.8	74.2	68.5	75.8	58.5	76.4	27.5	67.2		
16	63.2	64.4	69.3	73.0	66.9	74.9	55.5	75.2	23.5	65.0		
17	62.6	64.0	68.1	72.2	65.0	73.8	52.9	74.3	20.0	63.3		
18	61.7	63.2	66.9	71.4	63.6	73.2	48.8	73.1	17.1	62.7		
19	59.8	61.4	65.6	70.5	61.4	71.8	45.1	71.7	13.7	59.3		
20	58.6	60.3	64.3	69.6	59.9	71.3	41.6	70.1				

**Table 3c.** Observed (obs.) and relative (rel.) survival of patients with breast cancer (women) by age category for period 1988-2014 (N=53,166).






**Figure 4a.** Relative survival of patients with breast cancer (women) by pTNM. For 51,546 of 53,166 cases diagnosed between 1988 and 2014 valid data could be obtained for this item. For a total of 47,473 cases an evaluable classification was established. The grey line represents the subgroup of 5,693 patients with missing values regarding pTNM (10.7% of 53,166 patients, the percent values of all other categories are related to n=47,473).

							pTNM							
	pT1N	OM0	pT2N	IOM0	pT3N	0M0	pT4N	IOM0	pT1N	XM0	pT2N	IXM0	pT3N	XM0
	n=18	,636	n=7,	256	n=4	-56	n=3	322	n=9	25	n=7	732	n=	84
Years	obs. %	rel. %												
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	99.5	100.6	98.7	100.3	96.2	98.8	90.9	95.6	96.8	101.6	89.9	97.4	82.9	91.1
2	98.9	101.0	96.6	99.9	91.0	96.0	79.3	87.6	90.1	99.4	79.5	93.5	62.9	75.1
3	97.8	101.0	93.2	98.0	86.3	93.4	73.7	85.1	86.2	99.9	67.4	86.3	52.7	69.9
4	96.3	100.7	90.2	96.6	80.8	89.5	64.7	78.4	81.7	99.3	57.8	80.3	44.6	64.7
5	94.9	100.4	86.7	94.5	76.7	87.2	58.6	73.9	77.5	99.0	48.9	73.9	36.1	57.6
6	93.1	99.9	83.4	92.6	74.3	86.2	54.4	71.3	70.9	94.9	41.2	67.6	31.6	53.4
7	91.1	99.1	79.7	90.2	70.9	84.4	49.9	67.9	65.1	91.0	34.3	61.2		
8	89.4	98.6	77.0	88.8	66.8	81.5	47.3	66.7	60.7	88.7	28.2	54.5		
9	87.8	98.3	73.9	86.9	62.1	76.9	44.4	64.8	56.8	86.3	23.1	48.1		
10	85.9	97.8	71.0	85.1	58.7	74.2	40.2	61.2	52.3	82.9	20.1	45.0		
11	84.1	97.3	68.2	83.3	58.1	74.6	38.0	59.4	48.3	79.7	16.0	37.9		
12	81.9	96.4	64.9	80.9	55.6	72.8	34.9	56.8	44.3	75.9	12.4	31.3		
13	79.5	95.3	62.3	79.2	54.8	72.7	32.8	54.8	41.6	73.9	10.7	28.1		
14	77.5	94.5	59.4	77.1	51.3	69.1	31.2	53.4	39.5	72.5	8.7	23.8		
15	75.0	93.2	57.1	75.6	44.4	61.3	28.6	50.6	35.1	66.6	8.3	23.5		
16	72.8	92.2	54.9	74.3	43.3	59.6	25.8	48.4	31.9	63.1	8.3	23.7		
17	70.7	91.3	52.4	72.5	40.6	58.0	24.8	46.2	30.8	62.0				
18	68.3	90.1	50.4	71.2	40.6	57.8	22.4	44.7	28.9	60.4				
19	66.2	89.1	47.4	68.6	40.6	57.7	22.4	45.0	28.9	61.3				
20	64.2	88.1	45.7	67.8	38.6	56.4	22.4	45.3	27.9	60.4				

							pTNM							
cont'd	pT4N	IXM0	pT1N	I+M0	pT2N	I+M0	pT3N	I+M0	pT4N	I+M0	pT_N	I_M1	N.	Α
	n=2	226	n=5	934	n=7,	168	n=1,	224	n=1	168	n=3,	342	n=5,	693
Years	obs. %	rel. %												
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	74.7	82.5	99.2	100.2	97.6	99.1	95.0	96.6	88.4	91.9	71.8	73.5	93.7	95.6
2	57.4	69.6	97.1	99.0	92.2	95.0	86.9	89.8	74.1	79.9	53.8	56.2	86.7	90.1
3	45.5	60.7	94.2	97.2	86.2	90.2	78.1	82.0	61.1	68.1	40.0	42.6	80.3	84.7
4	37.2	54.2	91.3	95.2	80.4	85.4	71.2	75.9	52.2	60.4	30.3	32.9	75.0	80.3
5	32.8	52.3	88.4	93.3	75.2	81.1	65.5	70.9	43.5	52.1	23.4	25.9	70.5	76.6
6	28.8	50.6	85.0	90.9	71.0	77.8	59.5	65.4	36.5	45.1	18.6	21.0	67.3	74.2
7	22.8	43.3	81.8	88.6	66.9	74.5	53.6	59.6	32.1	40.8	15.5	17.8	63.4	70.8
8	17.0	34.9	79.5	87.2	62.8	71.0	49.8	56.3	29.2	38.3	13.3	15.6	60.4	68.5
9	14.8	31.5	76.7	85.2	59.2	68.1	45.7	52.6	25.9	34.9	11.9	14.2	57.2	65.8
10	12.5	28.8	73.2	82.5	55.8	65.2	42.4	49.5	23.7	32.7	10.3	12.7	54.3	63.4
11			71.0	81.1	53.2	63.2	40.3	47.8	22.0	31.0	9.1	11.3	51.0	60.6
12			68.3	79.2	50.5	60.9	37.9	45.6	19.6	28.3	8.5	10.9	48.2	58.3
13			65.8	77.6	47.7	58.5	35.0	42.8	17.5	26.1	8.0	10.4	45.5	56.0
14			63.3	75.8	45.5	56.9	32.3	39.8	15.1	22.9	7.0	9.4	43.6	54.7
15			60.9	74.2	43.6	55.3	28.3	35.7	14.9	23.0	6.2	8.6	41.3	52.8
16			57.6	71.4	41.7	54.0	28.3	35.8	13.6	21.5	5.8	8.2	38.4	50.2
17			55.9	70.6	39.9	52.7	26.6	34.0	12.5	20.4	4.9	7.3	36.1	48.2
18			53.6	68.8	37.7	50.7	23.9	31.0	11.5	19.2	4.4	6.7	34.2	46.7
19			50.7	66.4	35.9	49.2	22.7	30.0	11.2	19.1			30.8	43.0
20			48.7	64.9	34.3	47.8	21.3	28.5	11.2	19.2			29.0	41.4

**Table 4b.** Observed (obs.) and relative (rel.) survival of patients with breast cancer (women) by pTNM for period 1988-2014 (N=47,473).






**Figure 4c.** Relative survival of patients with breast cancer (women) by pTNM. For 41,644 of 42,608 cases diagnosed between 1998 and 2014 valid data could be obtained for this item. For a total of 37,833 cases an evaluable classification was established. The grey line represents the subgroup of 4,775 patients with missing values regarding pTNM (11.2% of 42,608 patients, the percent values of all other categories are related to n=37,833).

							pTNM							
	pT1N	OMOI	pT2N	10M0	pT3N	IOM0	pT4N	IOM0	pT1N	XM0	pT2N	IXM0	pT3N	XM0
	n=15	,474	n=5	,753	n=3	371	n=2	228	n=7	'01	n=5	588	n=	72
Years	obs. %	rel. %												
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	99.6	100.5	98.6	100.3	96.1	98.9	90.7	95.8	96.5	101.2	88.7	96.3	81.4	89.5
2	98.9	101.0	96.5	99.9	90.4	95.7	78.2	87.2	90.3	99.5	78.4	92.9	59.3	70.8
3	97.9	101.1	93.2	98.2	85.6	93.3	72.5	84.7	85.7	99.2	66.2	85.8	53.2	70.6
4	96.7	101.0	90.5	97.0	80.9	90.3	62.4	76.8	81.9	99.5	57.0	80.4	45.2	65.1
5	95.5	101.0	87.2	95.3	76.7	88.2	55.5	71.1	77.8	99.0	47.7	73.2	34.8	55.6
6	93.9	100.5	84.1	93.6	74.4	87.3	50.7	67.8	71.7	95.3	40.1	67.2	31.2	51.7
7	92.0	99.9	80.6	91.4	70.1	84.8	46.2	64.2	67.3	93.4	32.8	59.8		
8	90.5	99.6	78.2	90.4	66.5	82.6	44.8	63.8	62.4	90.5	26.7	53.0		
9	88.7	99.2	75.3	88.7	62.1	78.5	42.3	62.1	58.0	87.4	22.9	49.2		
10	86.8	98.6	72.2	86.9	58.2	75.4	38.3	59.2	53.3	83.6	19.1	44.3		
11	84.9	98.1	69.3	85.1	58.2	76.3	35.9	56.8	50.0	81.5	15.3	37.8		
12	82.9	97.5	66.4	83.2	53.3	71.7	35.9	56.9	46.5	78.5	11.2	29.9		
13	80.5	96.4	64.2	82.2	51.7	69.9	33.9	53.8	43.5	76.0	10.1	28.4		
14	79.2	96.4	62.0	81.1	49.0	68.1			42.5	75.7				
15	77.0	95.6	60.1	80.4					40.3	73.3				

							pTNM							
cont'd	'd pT4NXM0 pT1N+N n=163 n=4,61			I+M0	pT2N	I+M0	pT3N	I+M0	pT4N	I+M0	pT_N	I_M1	N.	Α
	n=1	163	n=4,	,618	n=5,	391	n=9	929	n=7	'51	n=2,	794	n=4,	775
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	73.6	81.9	99.4	100.4	97.6	99.1	95.6	97.3	87.8	91.6	71.7	73.4	93.2	95.1
2	57.3	70.2	97.6	99.6	93.2	96.1	87.9	91.2	73.6	80.0	53.7	56.1	85.7	89.0
3	43.9	59.8	95.3	98.2	88.0	92.1	79.8	84.4	61.2	69.0	40.3	42.9	78.7	82.9
4	36.4	54.5	93.0	97.0	83.1	88.4	73.4	78.9	52.7	61.7	31.0	33.6	73.0	77.8
5	33.3	55.1	90.8	95.8	78.1	84.5	68.6	74.8	45.1	54.7	23.7	26.2	68.2	73.7
6	29.1	53.5	88.3	94.3	74.3	81.6	63.1	69.9	38.7	48.6	19.2	21.6	65.2	71.3
7	20.9	42.2	85.7	92.7	70.1	78.3	57.4	64.5	33.9	44.1	16.0	18.3	61.3	67.7
8			83.5	91.6	66.0	74.9	54.6	62.2	31.3	42.2	13.7	16.1	57.8	64.7
9			80.9	89.9	62.6	72.3	50.3	58.6	27.5	38.0	12.0	14.3	54.9	62.2
10			77.6	87.5	59.0	69.3	46.3	54.7	24.5	34.7	10.2	12.5	51.8	59.2
11			75.6	86.4	56.4	67.3	44.1	52.6	21.7	31.3	8.7	10.8	49.6	57.4
12			73.3	85.2	54.5	66.1	40.5	48.9	19.9	29.7	8.1	10.4	47.3	55.5
13			70.7	83.5	51.6	63.8	38.9	47.4	19.9	29.7	7.8	9.9	44.0	52.5
14			68.7	82.3	49.6	62.3	35.0	42.8	19.9	29.6	6.7	8.7	41.9	50.5
15			66.0	80.6	48.5	62.0			19.9	29.5			38.9	47.5

**Table 4d.** Observed (obs.) and relative (rel.) survival of patients with breast cancer (women) by pTNM for period 1998-2014 (N=37,833).






**Figure 4e.** Conditional relative 5-year survival of patients with breast cancer (women) by extent of disease. For 51,546 of 53,166 cases diagnosed between 1988 and 2014 valid data could be obtained for this item. For a total of 51,333 cases an evaluable classification was established. The grey line represents the subgroup of 1,833 patients with missing values regarding extent of disease (3.4% of 53,166 patients, the percent values of all other categories are related to n=51,333).

			Exten	t of dis	sease			
	Loc	al	Regio	onal	Dista	ant	NA/N	IOS
		Cond.		Cond.		Cond.		Cond.
		surv. %		surv. %		surv. %		surv. %
Years	n	5 yrs	n	5 yrs	n	5 yrs	n	5 yrs
0	30,192	96.5	17,799	81.7	3,342	25.9	1,833	77.2
1	28,045	95.4	16,315	79.8	2,267	28.7	1,595	81.2
2	25,702	94.5	14,504	80.1	1,553	31.9	1,426	82.6
3	23,193	94.6	12,673	81.5	1,059	36.9	1,284	85.2
4	20,804	94.9	11,077	82.4	740	43.6	1,169	84.8
5	18,494	95.0	9,620	82.9	516	49.3	1,065	85.7
6	16,226	95.3	8,293	84.2	378	54.5	965	84.2
7	14,019	95.5	7,073	85.1	272	61.8	869	84.2
8	12,232	95.4	6,060	85.3	205	67.8	798	82.6
9	10,725	95.2	5,145	86.0	168	67.5	716	85.4
10	9,280	94.6	4,311	87.4	129	70.2	649	85.5

**Table 4f.** Conditional relative 5-year survival of patients with breast cancer (women) by extent of disease for period 1988-2014 (N=51,333).

Conditional relative survival rates refer to the relative survival probability, in this case for 5 years after cancer diagnosis, compared to the age- and sex-matched population (=100%) under the condition of being alive for a certain time period (x-axis in Figure 4c). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup extent of disease="Local", who are alive at least 3 years after cancer diagnosis, the conditional relative 5-year survival rate is 94.6% (n=23,193).




**Figure 5a.** Time to first progression of 39,770 patients with breast cancer (women) diagnosed between 1998 and 2014 (M0 only in solid cancers) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

Type of progression							
	Any type (CI)	Any type (1-KM)				Lymph node (1-KM)	Distant metastasis (CI)
	n=39,770	n=39,770	n=39,770	n=39,770	n=39,770	n=39,770	n=39,770
Years	%	%	%	%	%	%	%
0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
1	3.0	3.1	0.8	8.0	0.3	0.3	1.9
2	7.3	7.5	2.2	2.3	0.9	0.9	4.9
3	10.7	11.0	3.4	3.5	1.3	1.4	7.5
4	13.4	13.8	4.2	4.5	1.6	1.8	9.6
5	15.5	16.2	5.0	5.4	1.9	2.1	11.4
6	17.4	18.3	5.7	6.3	2.2	2.4	12.7
7	19.1	20.2	6.3	7.0	2.4	2.7	14.2
8	20.7	22.1	6.9	7.8	2.6	2.9	15.3
9	22.0	23.6	7.5	8.6	2.7	3.1	16.3
10	23.2	25.1	8.1	9.5	2.9	3.3	17.1
11	24.2	26.4	8.5	10.1	2.9	3.4	17.8
12	25.0	27.5	8.8	10.7	3.0	3.6	18.4
13	25.8	28.6	9.3	11.4	3.2	3.8	19.0
14	26.5	29.5	9.7	12.1	3.3	4.0	19.4
15	27.1	30.3	10.1	12.8	3.4	4.2	19.8

Type of progression  Distant					
cont'd	metast. (1- KM)	NOS (CI)	NOS (1-KM)		
	n=39,770	n=39,770	n=39,770		
Years	%	%	%		
0	0.0	0.0	0.0		
1	1.9	0.2	0.2		
2	5.1	0.4	0.4		
3	7.8	0.5	0.6		
4	10.0	0.6	0.7		
5	12.0	0.7	8.0		
6	13.5	0.7	8.0		
7	15.2	8.0	0.9		
8	16.6	8.0	1.0		
9	17.7	0.9	1.0		
10	18.7	0.9	1.1		
11	19.7	1.0	1.1		
12	20.4	1.0	1.2		
13	21.3	1.0	1.2		
14	21.9	1.0	1.3		
15	22.4	1.0	1.3		

**Table 5b.** Time to first progression of patients with breast cancer (women) for period 1998-2014 (N=39,770).




**Figure 5c.** Observed post-progression survival of 8,357 patients with breast cancer (women) diagnosed between 1998 and 2014. These 8,357 patients with documented progression events during their course of disease represent 19.7% of the totally 42,515 evaluated cases (incl. M1, n=2,745, 6.5%). Patients with cancer relapse documented via death certificates only were excluded (n=1,292, 3.0%). Multiple progression types on different sites are included in the evaluation even when not occurring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement "not specified" is the only information in registries regarding relapse of the disease. The category "Any type" denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100% value because patients are potientially considered in more than one subgroup.

Type of progression					
	Any type	Local relapse	Lymph node	Distant metastasis	NOS
	n=8,357	n=2,513	n=925	n=6,683	n=291
Years	%	%	%	%	%
0	100.0	100.0	100.0	100.0	100.0
1	73.9	83.2	79.6	67.0	77.8
2	57.0	69.7	60.2	48.0	63.0
3	44.9	60.9	48.2	34.7	51.8
4	36.7	54.5	40.8	25.9	48.0
5	30.7	49.8	35.0	19.7	45.2
6	26.0	44.8	29.6	15.5	40.4
7	22.9	41.0	26.0	12.7	39.6
8	20.7	38.6	25.3	11.0	36.6
9	18.9	35.7	23.6	9.8	36.6
10	17.2	33.2	22.2	8.6	33.6

**Table 5d.** Observed post-progression survival of patients with breast cancer (women) for period 1998-2014 (N=8,357).



**Figure 5e.** Observed post-progression (distant metastasis) survival of 9,574 patients with breast cancer (women) diagnosed between 1988 and 2014 by period of progression.

Period of progression							
1988-1997		1998-2006	2007+				
	n=1,586	n=3,527	n=4,461				
Years	%	%	%				
0	100.0	100.0	100.0				
1	67.2	68.1	68.1				
2	44.4	48.8	50.3				
3	31.3	35.8	36.9				
4	22.5	27.0	27.4				
5	17.4	20.6	21.2				
6	13.5	16.0	17.1				
7	11.6	12.8	14.6				
8	10.2	10.8	12.6				
9	9.2	9.3					
10	8.2	8.0					

**Table 5f.** Observed post-progression (distant metastasis) survival of patients with breast cancer (women) for period 1988-2014 by period of progression (N=9,574).

#### **Shortcuts**

MCR	Munich Cancer Registry, Germany				
NCI	National Cancer Institute, USA				
SEER	Surveillance, Epidemiology, and End Results, USA				
UICC	Union for International Cancer Control, Geneva				
DCO	Death certificate only	Death certificate provides the only notification to the registry.			
NA	Not available				
NOS	Not otherwise specified				
os	Overall/Observed survival	Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause			
RS	Relative survival	Survival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival			
AS	Assembled survival	Assembled chart of observed, expected, relative survival			
CS	Conditional survival	Survival probability under the condition of surviving a given period of time			
TTP	Time to progression	Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression			
	1-KM	1 minus Kaplan-Meier estimator ("inverse" Kaplan-Meier estimator)			
	CI	Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice)			
PPS	Post-progression survival	Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause			

#### **Recommended Citation**

Munich Cancer Registry. Survival ICD-10 C50: Breast cancer (women) [Internet]. 2016 [updated 2016 Apr 11; cited 2016 Jun 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/surv/sC50f\_E-ICD-10-C50-Breast-cancer-women-survival.pdf

#### Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

#### **Disclaimer**

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

### Index of figures and tables

F	ig./Tbl	l.	Page
	1a	Relative survival by period of diagnosis (chart)	2
	1b	Survival by period of diagnosis (table)	2
	1c	Relative survival by year of diagnosis (chart)	3
	1d	Survival by year of diagnosis (table)	3
	2a	Survival of total cohort (chart)	5
	2b	Survival of total cohort (table)	5
	3a	Observed survival by age category (chart)	6
	3b	Relative survival by age category (chart)	6
	3c	Survival by age category (table)	7
	4a	Relative survival by pTNM 1988+ (chart)	8
	4b	Survival by pTNM 1988+ (table)	8
	4c	Relative survival by pTNM 1998+ (chart)	10
	4d	Survival by pTNM 1998+ (table)	10
	4e	Conditional survival by extent of disease (chart)	12
	4f	Conditional survival by extent of disease (table)	12
	5a	Time to first progression (chart)	13
	5b	Time to first progression (table)	13
	5c	Observed post-progression survival (chart)	15
	5d	Observed post-progression survival (table)	15
	5e	Observed post-progression survival by period of progression (chart)	16
	5f	Observed post-progression survival by period of progression (table)	16